Patents-Review.com
🔗 Permalink
Inventor profile of:

Peter Wipf

City:

Pittsburgh, Pennsylvania

Country:

United States

Published Applications:

96

Last publication date:

2026-05-28

Top Assignees for applications by Peter Wipf

The entities that hold a legal rights for patent applications filed by inventor Wipf Peter:

Recent patent applications by Wipf Peter

Peter Wipf from Pittsburgh, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-05-28
US20260144752A1
Human necessities

Multilamellar Vesicles and Methods and Uses Thereof

 #2 | 2026-03-26
US20260083751A1
Human necessities

ALLOSTERIC MODULATORS OF ANDROGEN RECEPTOR COACTIVATOR RECRUITMENT FOR CRPC THERAPY

 #3 | 2025-05-15
US20250154188A1
Chemistry; metallurgy

C-GLYCOSIDES AS ANTI-INFLAMMATORY AGENTS

 #4 | 2024-10-17
US20240343692A1
Chemistry; metallurgy

SELECTIVE PSYCHEDELIC COMPOUNDS

 #5 | 2024-02-15
US20240051931A1
Chemistry; metallurgy

HDAC INHIBITORS

 #6 | 2023-11-09
US20230357261A1
Chemistry; metallurgy

ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS

 #7 | 2023-04-27
US20230131668A1
Chemistry; metallurgy

HEAT SHOCK PROTEIN MODULATORS AND ANTI-HUNTINGTON DISEASE THERAPEUTIC AGENTS

 #8 | 2022-08-18
US20220259149A1
Chemistry; metallurgy

Targeted Nitroxide Compounds and Their Use in Treating Ferroptosis-Related Diseases

 #9 | 2022-06-30
US20220202800A1
Human necessities

Method of treatment of organic acidemias and other mitochondria defects or deficiencies

 #10 | 2022-04-14
US20220112179A1
Chemistry; metallurgy

METHODS OF TREATMENT USING PHENYL INDOLE ALLOSTERIC INHIBITORS OF P97 ATPASE

 #11 | 2022-03-24
US20220089565A1
Chemistry; metallurgy

Modulators of p97 AAA ATPase activity

 #12 | 2022-01-20
US20220017534A1
Chemistry; metallurgy

In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors

 #13 | 2021-12-23
US20210395266A1
Chemistry; metallurgy

In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors

 #14 | 2021-12-09
US20210379191A1
Human necessities

Mitochondrially targeted PARP inhibitor, and uses thereof

 #15 | 2021-12-02
US20210371460A1
Chemistry; metallurgy

TARGETED NITROXIDE AGENTS

 #16 | 2021-10-07
US20210308162A1
Human necessities

NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS

 #17 | 2021-08-05
US20210238129A1
Chemistry; metallurgy

Selective potassium channel agonists

 #18 | 2021-06-24
US20210186963A1
Human necessities

Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer

 #19 | 2021-05-06
US20210128594A1
Human necessities

Compositions and methods for treatment of inflammatory disorders

 #20 | 2021-03-11
US20210070732A1
Chemistry; metallurgy

MODULATORS OF P97 AAA ATPASE ACTIVITY

 #21 | 2021-03-04
US20210061779A1
Chemistry; metallurgy

Compounds for treating prostate cancer

 #22 | 2021-02-04
US20210032221A1
Chemistry; metallurgy

1,2,3-triazole inhibitors of P97 AAA ATPase activity

 #23 | 2020-10-29
US20200339602A1
Chemistry; metallurgy

6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity

 #24 | 2020-10-08
US20200317730A1
Chemistry; metallurgy

TARGETED NITROXIDE AGENTS

 #25 | 2020-07-09
US20200216410A1
Chemistry; metallurgy

Modulators of P97 AAA ATPase activity

 #26 | 2020-05-21
US20200157082A1
Chemistry; metallurgy

Phenyl indole allosteric inhibitors of P97 ATPase

 #27 | 2020-05-07
US20200140387A1
Chemistry; metallurgy

Tetrahydroisoquinolines as selective NADPH oxidase 2 inhibitors

 #28 | 2020-03-26
US20200095220A1
Chemistry; metallurgy

Substituted β-lapachones for treating cancer

 #29 | 2020-02-06
US20200038518A1
Human necessities

Mitochondrially targeted PARP inhibitor, and uses thereof

 #30 | 2020-01-02
US20200000793A1
Human necessities

TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS

 #31 | 2019-12-12
US20190374562A1
Human necessities

TLR4 inhibitors for the treatment of human infectious and inflammatory disorders

 #32 | 2019-07-11
US20190210969A1
Chemistry; metallurgy

INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS

 #33 | 2019-06-20
US20190185448A1
Chemistry; metallurgy

Modulators of P97 AAA ATPase activity

 #34 | 2019-05-16
US20190142893A1
Human necessities

Electron, Radical, or Reactive Oxygen Species-Scavenging Agent Based Therapy of Inborn Errors of Fatty Acid Oxidation and Oxidative Phosphorylation

 #35 | 2019-04-04
US20190100535A1
Chemistry; metallurgy

6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity

 #36 | 2019-03-21
US20190084984A1
Chemistry; metallurgy

Calcium channel agonists

 #37 | 2019-02-07
US20190038556A1
Human necessities

FORMULATIONS AND CARRIER SYSTEMS INCLUDING COMPOUND INTERACTIVE DOMAINS

 #38 | 2019-01-24
US20190022093A1
Human necessities

Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer

 #39 | 2018-11-08
US20180319778A1
Chemistry; metallurgy

Phenyl indole allosteric inhibitors of p97 ATPase

 #40 | 2018-10-18
US20180298054A1
Chemistry; metallurgy

Targeted nitroxide agents

 #41 | 2018-10-04
US20180280418A1
Human necessities

Compositions and methods for treatment of inflammatory disorders

 #42 | 2018-08-23
US20180237403A1
Chemistry; metallurgy

Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer

 #43 | 2018-07-05
US20180185322A1
Human necessities

Compounds for bone healing

 #44 | 2018-06-21
US20180170946A1
Chemistry; metallurgy

Inhibitors of PTP4A3 for the treatment of cancer

 #45 | 2018-06-21
US20180170895A1
Chemistry; metallurgy

Substituted β-lapachones for treating cancer

 #46 | 2018-05-10
US20180127357A1
Chemistry; metallurgy

(2-amino-4-(arylamino)phenyl carbamates

 #47 | 2018-01-11
US20180009810A1
Chemistry; metallurgy

Calcium channel agonists

 #48 | 2018-01-11
US20180009762A1
Chemistry; metallurgy

TETRAHYDROISOQUINOLINES AS SELECTIVE NADPH OXIDASE 2 INHIBITORS

 #49 | 2017-08-31
US20170247382A1
Chemistry; metallurgy

Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer

 #50 | 2017-08-31
US20170246164A1
Human necessities

Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer

 #51 | 2017-08-10
US20170226074A1
Chemistry; metallurgy

Antifibrotic effects of oxetanyl sulfoxides

 #52 | 2017-04-20
US20170107190A1
Chemistry; metallurgy

Antifibrotic effects of oxetanyl sulfoxides

 #53 | 2017-04-06
US20170095493A1
Human necessities

TLR4 inhibitors for the treatment of human infectious and inflammatory disorders

 #54 | 2017-04-06
US20170095478A1
Human necessities

Combination therapy to enhance the anticancer efficacy of platinum drugs

 #55 | 2016-09-15
US20160264540A1
Chemistry; metallurgy

Compounds for treating prostate cancer

 #56 | 2016-09-08
US20160257657A1
Chemistry; metallurgy

SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

 #57 | 2016-06-23
US20160176836A1
Chemistry; metallurgy

Bifunctional compounds

 #58 | 2016-06-02
US20160151269A1
Human necessities

Compounds for the treatment of pathologies associated with aging and degenerative disorders

 #59 | 2016-05-19
US20160137692A1
Chemistry; metallurgy

Targeted nitroxide agents

 #60 | 2016-05-12
US20160128938A9
Human necessities

Formulations and carrier systems including compound interactive domains

 #61 | 2016-03-31
US20160090387A1
Chemistry; metallurgy

Calcium channel agonists

 #62 | 2016-03-24
US20160083351A1
Chemistry; metallurgy

Tetrahydroisoquinolines as selective NADPH oxidase 2 inhibitors

 #63 | 2016-03-10
US20160068556A1
Chemistry; metallurgy

Targeted nitroxide agents

 #64 | 2016-01-14
US20160008127A1
Human necessities

Prosthetic implant for medialization thyroplasty

 #65 | 2015-10-29
US20150306034A1
Human necessities

Formulations and carrier systems including compound interactive domains

 #66 | 2015-10-22
US20150297578A1
Human necessities

Selective targeting agents for mitochondria

 #67 | 2015-09-10
US20150250809A1
Human necessities

TLR4 inhibitors for the treatment of human infectious and inflammatory disorders

 #68 | 2015-01-15
US20150018346A1
Human necessities

Compounds for the treatment of pathologies associated with aging and degenerative disorders

 #69 | 2014-12-25
US20140378444A1
Chemistry; metallurgy

Targeted nitroxide agents

 #70 | 2014-12-18
US20140371235A1
Chemistry; metallurgy

Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer

 #71 | 2014-09-11
US20140256654A1
Chemistry; metallurgy

Bifunctional compounds

 #72 | 2014-07-17
US20140199368A1
Chemistry; metallurgy

INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS

 #73 | 2014-04-17
US20140107317A1
Chemistry; metallurgy

Selective targeting agents for mitochondria

 #74 | 2014-02-13
US20140045821A1
Chemistry; metallurgy

Protein kinase D inhibitors

 #75 | 2014-01-16
US20140018317A1
Chemistry; metallurgy

Targeted nitroxide agents

 #76 | 2013-12-12
US20130331460A1
Chemistry; metallurgy

Chrysophaentin analogs that inhibit FtsZ protein

 #77 | 2013-10-24
US20130281395A1
Human necessities

TLR4 inhibitors for the treatment of human infectious and inflammatory disorders

 #78 | 2013-04-25
US20130102626A1
Chemistry; metallurgy

Targeted nitroxide agents

 #79 | 2012-10-04
US20120252733A1
Human necessities

Use of targeted nitroxide agents in bone healing

 #80 | 2012-08-16
US20120207687A1
Human necessities

TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS

 #81 | 2012-01-05
US20120004263A1
Human necessities

Compounds for the treatment of pathologies associated with aging and degenerative disorders

 #82 | 2011-07-14
US20110172214A1
Human necessities

Use of targeted nitroxide agents in mitigating or treating radiation injury

 #83 | 2011-05-12
US20110110941A1
Chemistry; metallurgy

Wortmannin Analogs and Methods of Using Same in Combination with Chemotherapeutic Agents

 #84 | 2011-02-17
US20110039792A1
Human necessities

Selective Targeting Agents for Mitochondria

 #85 | 2010-05-18
US11565779
-

Selective targeting agents for mitochondria

 #86 | 2010-02-25
US20100047841A1
Chemistry; metallurgy

SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF

 #87 | 2010-02-11
US20100035869A1
Chemistry; metallurgy

Targeted nitroxide agents

 #88 | 2009-05-21
US20090131511A1
Chemistry; metallurgy

Palmarumycin based inhibitors of thioredoxin and methods of using same

 #89 | 2009-04-02
US20090087441A1
Chemistry; metallurgy

Wortmannin analogs and methods of using same in combination with chemotherapeutic agents

 #90 | 2009-02-12
US20090042808A1
Human necessities

Use of mitochondria-targeted electron scavengers as anti-inflammatory agents

 #91 | 2008-05-29
US20080125479A1
Human necessities

Wortmannin analogs and methods of using same

 #92 | 2007-07-12
US20070161573A1
Human necessities

Selective targeting agents for mitochondria

 #93 | 2007-07-12
US20070161544A1
Human necessities

SELECTIVE TARGETING AGENTS FOR MITCOCHONDRIA

 #94 | 2006-07-27
US20060167080A1
Human necessities

Wortmannin analogs and methods of using same

 #95 | 2006-03-23
US20060063824A1
Chemistry; metallurgy

Wortmannin analogs and methods of using same in combination with chemotherapeutic agents

 #96 | 2005-06-30
US20050143434A1
Chemistry; metallurgy

Benzo[d]isoxazol-3-ol DAAO inhibitors
InventorID:

211388 ⎘